The company is experiencing mixed performance with a recent one-day share price decline but strong 90-day and one-year returns. Key growth drivers include expansion of its TAVR treatment populations and ongoing clinical evidence. However, near-term outlook is clouded by macroeconomic pressures and foreign exchange headwinds. The company is targeting 10% growth by 2026 and is soon announcing fiscal fourth-quarter earnings, where analysts project single-digit earnings growth. Current valuation is considered premium relative to its price-to-earnings ratio.